{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070948","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.724498+00:00","generated_at":"2026-05-21T09:43:33.808273+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health enters $4.1M GMP manufacturing agreement with Scorpius for Entolimod ARS","bullets":["Scorpius BioManufacturing to perform GMP validation for Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS).","Total estimated investment ~$4.1M comprising ~$2.4M service fees and pass-through costs for consumables, external services.","Scorpius to perform cell line verification, GMP scale-up, fill/finish, analytical development, process optimization.","Purpose is to prepare complete CMC package for FDA BLA submission for Entolimod.","Manufacturing at Scorpius' San Antonio, TX facility; aims for leaner supply chain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070948","json":"https://secwatch.observer/filing/0000950170-25-070948.json","markdown":"https://secwatch.observer/filing/0000950170-25-070948.md","text":"https://secwatch.observer/filing/0000950170-25-070948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/0000950170-25-070948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/tivc-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:43:33.808273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}